Tango Therapeutics (TNGX) Capital Expenditures Growth (3y) (2023 - 2026)
Tango Therapeutics (TNGX) Capital Expenditures Growth (3y) (2023 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Capex Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 67,583.17 Bn | 67,582.89 Bn | - | - |
| 2 | Nanobiotix | 1,947.22 Bn | 1,947.15 Bn | - | - |
| 3 | Akari Therapeutics | 1,132.35 Bn | 1,132.35 Bn | - | - |
| 4 | BeOne Medicines | 473.21 Bn | 468.42 Bn | 1.35 Bn | -12.25% |
| 5 | Vertex Pharmaceuticals | 123.29 Bn | 116.04 Bn | 2.59 Bn | 46.88% |
| 6 | Regeneron Pharmaceuticals | 70.05 Bn | 61.29 Bn | 3.31 Bn | 8.97% |
| 7 | Belite Bio | 63.09 Bn | 63.09 Bn | - | - |
| 8 | Argenx Se | 56.63 Bn | 51.45 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.79 Bn | 37.79 Bn | - | - |
| 10 | Tango Therapeutics | 3.91 Bn | 3.75 Bn | - | -26.33% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -26.33% |
| Dec 31, 2025 | -58.02% |
| Sep 30, 2025 | -26.26% |
| Jun 30, 2025 | 35.76% |
| Mar 31, 2025 | -53.28% |
| Dec 31, 2024 | 70.95% |
| Sep 30, 2024 | -48.53% |
| Jun 30, 2024 | 72.02% |
| Mar 31, 2024 | -30.30% |
| Dec 31, 2023 | -46.56% |